跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 829 条关于
“CheckMate 649”
全部
829
临床试验
370
药物
236
机构
5
资讯
218
去年
Nivolumab Plus Chemotherapy Demonstrates Sustained Survival Benefit in Advanced Gastroesophageal Cancers
去年
FDA Advisory Committee Recommends Against Checkpoint Inhibitors for Certain Gastroesophageal Cancers
去年
FLOT Regimen Emerges as Superior Treatment for Localized Gastroesophageal Cancer, Outperforming Radiation Therapy
去年
Immunotherapy Combinations Transform Advanced Squamous Cell Anal Cancer Treatment Landscape
去年
Advancements in Gastroesophageal Cancer: FLOT Regimens, HER2 Inhibition, and Zolbetuximab
去年
PD-L1 Expression Thresholds in Gastrointestinal Cancers Under Scrutiny for PD-1 Inhibitor Efficacy
去年
Comprehensive Review Identifies Key Biomarkers for Predicting Gastric Cancer Immunotherapy Response
10个月前
CheckMate 648 and KEYNOTE-590 Establish Chemo-Immunotherapy as First-Line Standard for Advanced Esophageal Squamous Cell Carcinoma
去年
CheckMate 901: Nivolumab Plus Chemotherapy Improves Survival in Advanced Urothelial Carcinoma
2年前
Perioperative Nivolumab and Neoadjuvant Immunotherapy Show Promise in Resectable NSCLC
第 1 页,共 22 页
上一页
下一页